Cardiovascular, Renal and Metabolism (CVRM)

Saving lives by seeing the full picture and jointly addressing cardio-renal-metabolic risks

A World of Close Collaborative Care for CVRM Patients

At AstraZeneca, CVRM (Cardiovascular, Renal and Metabolism) is one of our main therapy areas because science continues to uncover commonalities between metabolism, heart failure, arterial vascular disease and renal disease – four distinct but interrelated areas. With this knowledge, we are daring to do things differently by shifting focus from treating patients with a single disease, to addressing overlapping disease areas and risk factors.

Cardiovascular, renal and metabolic diseases kill up to 20 million people each year1 and despite the close associations between these disease areas, shared risk factors may still often not be diagnosed or addressed2. For example, if you are an adult with diabetes, you could be 1.8 times more likely to be hospitalised for a heart attack than an adult without diabetes3. If we look at diabetes and kidney disease combined, life expectancy can be reduced by up to 15 years for men and 16 years for women4.

We have made it our mission to help protect up to 130 million people from the often-devastating consequences of CVRM diseases by 2025. We work with cardiovascular, renal and diabetes experts from around the world, who are led by science and fuelled by investigation to adapt a proactive, collaborative, and multidisciplinary approach to patient care.

By taking risks in research, science and investigation, we systematically study compounds across the CVRM diseases and in different combinations – striving to create uncharted pathways of clinical exploration. This first-class clinical research and real-world evidence help us understand the interactions between two or more conditions, and how the deterioration of one condition could adversely affect the others. It also sets the stage for our pioneering approach in the fields of disease regression and organ regeneration, putting us a step closer to making science fiction a reality.



Driven by collaboration

We cannot change the future alone. We are actively investing in broader and stronger partnerships with respected academic institutions, research organisations, patient advocacy groups, and healthcare companies. We are paving the way for clinical practice evolution, and we are using close collaboration as our brick foundation.

We make it our responsibility to help healthcare professionals connect the dots, evolve their clinical practice and provide complete, potentially life-saving care for CVRM patients. Our role is to offer healthcare professionals the best possible solutions to enable them to think holistically and work in closer collaboration during everyday care and across individual specialties. Most importantly, it is through partnering with general practitioners that they can protect patients against heart and renal failure, improve health and save the lives of millions of people living with these diseases.

 

Our focus on unmet needs

Arterial Vascular Disease


There were approximately 111 million cases of ischaemic heart disease globally in 2015, and cardiovascular diseases are the leading cause of death worldwide with about 17.9 million people dying every year.5, 6

 


Heart Failure


There are 64 million heart failure patients worldwide, with many suffering from at least one other underlying condition such as type-2 diabetes.7,8


 


Renal


Chronic kidney disease (CKD) can be a complex, debilitating condition with an estimated 200 million adults diagnosed worldwide.9


 


Metabolic Disease


Diabetes is a growing disease and an enormous global burden that is currently projected to affect more than 629 million people by the year 2045.10


 


Resources

Helping save lives by jointly addressing cardio-renal-metabolic risks

Watch how our unique science-driven strategy in cardiovascular, renal and metabolism is helping us to complete the picture.



Understanding the common mechanisms and how CVRM diseases interact


Learn more about our ambitious strategy.



Our early-to-late stage pipeline for CVRM

Today, we believe we are the only pharmaceutical company with a full portfolio of potential CVRM solutions. With more than 25 therapies and therapy combinations in our early-to-late stage pipeline, we seek to bring real science to life, combatting conditions like CKD, ACS, and CHF.



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

 

Cardiovascular, Renal and Metabolism (as at 25 July 2019)

Phase I

Phase I

  • AZD8233 CV disease
  • AZD9977 CV disease
  • MEDI6570 cardiovascular disease
  • MEDI7219 type-2 diabetes

Phase II

Phase II

  • AZD4831 heart failure with a preserved ejection fraction
  • AZD5718 coronary artery disease
  • AZD8601 cardiovascular disease
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease
  • cotadutide type-2 diabetes and obesity
  • verinurad chronic kidney disease

Phase III

Phase III

  • Epanova severe hypertriglyceridaemia
  • Lokelma hyperkalaemia
  • roxadustat OLYMPUS ROCKIES anaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/Brilique THALES acute ischaemic stroke or transient ischaemic attack
  • Brilinta/Brilique HESTIA prevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/Brilique THEMIS cardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon EXSCEL type-2 diabetes outcomes study
  • Bydureon BCise (autoinjector) type-2 diabetes
  • Epanova STRENGTH cardiovascular outcomes study in statin-treated patients at high cardiovascular risk, with persistent hypertriglyceridemia plus low HDL-cholesterol
  • Farxiga/Forxiga DECLARE- TIMI 58 cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/Forxiga DELIVER worsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/Forxiga DEPICT type-1 diabetes
  • Farxiga/Forxiga DETERMINE-Preserved heart failure with preserved ejection fraction (HFpEF)
  • Farxiga/Forxiga DETERMINE-Reduced heart failure with reduced ejection fraction (HFrEF)
  • Farxiga/Forxiga Dapa-CKD renal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/Forxiga Dapa-HF worsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Qternmet XR (saxagliptin/dapagliflozin metformin) type-2 diabetes
  • Xigduo XR/Xigduo type-2 diabetes
  • roxadustat anaemia in myelodysplastic syndrome


Our medicines

We cannot provide detailed information about our prescription medicines on this website, in compliance with regulations. Our medicines are approved in individual countries for specific uses and the information we provide for patients is governed by local regulations. In some cases, health care professionals and patients can visit local AstraZeneca websites to find out more about our medicines. Please note that in some countries we are not allowed to provide very much, or sometimes any, information on our prescription medicines so you should seek alternative trustworthy sources. Always ask a healthcare professional for advice about medicines.



Atacand, Atacand HCT, Atacand Plus

candesartan cilexetil

Brilinta/Brilique

ticagrelor

Bydureon

exenatide

Byetta

exenatide injection

Crestor

rosuvastatin

Farxiga/Forxiga

dapagliflozin

Komboglyze

saxagliptin and metformin HCl

Kombiglyze XR

saxagliptin and metformin XR

Lokelma

Sodium zirconium cyclosilicate

Onglyza

saxagliptin

Plendil, Modip, Splendil, Munobal, Flodil 

felodipine

Qtern

dapagliflozin and saxagliptin

Seloken ZOK, Toprol-XL, Betaloc ZOK

metoprolol succinate

Symlin

pramlintide acetate

Tenormin, Tenormine, Prenormine, Atenol 

atenolol

XIGDUO

dapagliflozin and metformin HCI

XIGDUO XR 

dapagliflozin and metformin HCI extended-release

Zestril

lisinopril dihydrate



Sharing clinical trials information



References

  1. Wang H et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet 2016; 388(10053):1459–544.
  2. Edelman Intelligence Relevance and barriers amongst EU specialists Survey 2018. Document ID: Z2-0050 | Date of preparation: August 2018 | Date of expiry: July 2020
  3. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2014: Centers for Disease Control and Preventions Division of Diabetes Translation [cited 2018 Jul 25]. Available from: URL: https://www.cdc.gov/diabetes/pdfs/data/2014-report-estimates-of-diabetes-and-its-burden-in-the-united-states.pdf
  4. Wen CP et al. Diabetes with early kidney involvement may shorten life expectancy by 16 years. Kidney Int 2017; 92(2):388–96. 
  5. World Health Organization. WHO World Heart Day: Scale up prevention of heart attack and stroke: World Health Organization; 2019 [cited 2019 Feb 19]. Available from: URL: https://www.who.int/cardiovascular_diseases/world-heart-day/en/.
  6. Roth GA et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol 2017; 70(1):1–25.
  7. Vos T et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet 2017; 390(10100):1211–59.
  8. Lawson CA et al. Comorbidity health pathways in heart failure patients: A sequences-of-regressions analysis using cross-sectional data from 10,575 patients in the Swedish Heart Failure Registry. PLoS Med 2018; 15(3):e1002540.
  9. Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 2014; 125:229-43; discussion 243-6.
  10. Ogurtsova K et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128:40–50.

Veeva ID: Z4-17494    

Date of next review: 07/06/2021